Vactosertib not checked

MedPacto, Inc. · TEW-7197

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
6 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“Vactosertib is given twice a day, five days on and two days off in four-week cycles. Vactosertib is a transforming growth factor-beta (TGF-β) type 1 receptor inhibitor.”In the company’s words, NCT05588648 on ClinicalTrials.gov
Tested for
Osteosarcoma
Main trialPhase 1/2
“MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 12 years of age and older who meet the criteria for study enrollment.”In the company’s words, NCT05588648 on ClinicalTrials.gov
Other names
TEW-7197 · vactosetib

Other drugs for Osteosarcoma

All 20 drugs for Osteosarcoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Dec 2027 Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
Phase 2Withdrawn 23 May 2022 Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
Phase 1/2Completed 3 Jan 2022 TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer
Phase 1/2Completed 7 May 2024 Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
Phase 1/2Completed 17 May 2024 Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
Phase 1Completed 31 Dec 2019 Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Vactosertib

Following is part of Solo: you see every change to Vactosertib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in